Thus, it is reasonably speculated that multitargeted small molecule inhibitors that inhibit FGFR1 along with other functional proteins, such as LIN28, may exert the strongest effects in the clinical treatment of NSCLC. The gene discussed is FGFR1; the disease is non-small cell lung carcinoma.